Merck's quadrivalent and nine-valent HPV vaccines will work together to build a stronger health shield for women aged 9-45 in China

On August 30, 2022, Merck (Merck is the company name of Merck corporation in Rowe, New Jersey, USA) announced that the new indications for its nine-valent human papillomavirus vaccine (Saccharomyces cerevisiae) (hereinafter referred to as the "nine-valent HPV vaccine") have been approved by the State Drug Administration of China, marking the expansion of merck's nine-valent HPV vaccine to women

The nine-valent HPV vaccine uses a three-dose immunization program for the prevention of cervical cancer caused by HPV 16, 18, 31, 33, 45, 52 and 58; Cervical intraepithelial neoplasia (grade CIN1/2/3) and cervical adenocarcinoma in situ (AIS) caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and persistent infections

Cervical cancer is one

Professor Qiao Youlin of the School of Group Medicine and Public Health of the Chinese Academy of Medical Sciences and Peking Union Medical College pointed out that the HPV vaccine for adolescent girls is easy to stimulate a better immune response, and women who have not had sex will get the best preventive effect

"In order to reduce the threat of cervical cancer to women's health, in recent years, China attaches great importance to the comprehensive

Dr.

Anna Van Acker, Senior Vice President of MERCK Worldwide and President of Merck China, said: "Eliminating cervical cancer is a vision shared by all of humanity, and Merck is committed to protecting the health